Over the past few decades, advancements in computing power, machine learning and data processing have changed the world; now they represent one of the biggest promises for the future of medicine… Among its numerous medical applications, computer technology allows for building complex computational models – of a protein or an organ, for instance – to run simulations and test the possible outcomes of a new therapy or drug. Coupled with our knowledge of the human genome, these predictive tools constitute the basis of personalized medicine, an approach tailoring treatments to each individual patient.
Riccardo Sabatini, scientist and entrepreneur, is one of the founders of Orionis Biosciences, a U.S. biotechnology firm working on genome-based drug design. A renowned international speaker (his TED2016 talk received over 1.7 million views), Sabatini is specialized in numerical modeling of complex systems, which over the years has led him to work – along with scientists of the caliber of Craig Venter – in market forecasting, artificial intelligence and computational genomics. Sabatini was also one of the young innovators in health invited by Barack Obama to speak at The White House Frontiers Conference 2016.
We asked Sabatini about his current projects, the state of computational medicine and the impact of supercomputers.
Q:what are you working on at the moment?
A: I’m working on a new platform to discover drug interactions across the entire human proteome, with an extension to hundreds of rare-diseases alleles. Drug design went through several phases in history, moving from a phenotypic screening process to a target-based one. I believe genome-wide drug design represents the next era of medicine, allowing us to tackle diseases we’re still struggling to hit.
Q:How close are we to computer-based, personalized medicine?
A: It’s a very complex challenge, and still far from everyday applications, but we’re getting better and better. Right now, we are focusing on how to predict if a patient would respond in an unexpected way to a specific drug – an indication that can help clinical teams to select another molecule or tune the dosage of the current one. Or to discover new uses for old drugs. Thanks to modern crystallography and new numerical methods, we’ll soon be able to run these tests in silico (using computer software or simulation).
Q:How does computational, genome-based drug design work?
A: Starting from a three-dimensional “picture” of a protein, a crystallographic reconstruction typically realized with nuclear magnetic resonance and electron cryomicroscopy, we can simulate the possible folds of the protein, searching for possible “attack” points for a drug. Also, once the protein-drug interaction is known we can analyze mutations of that protein, specific for a certain subpopulation or single individual, simulating the different behavior and computing the reduction or growth of the drug engagement – a representation of the drug potency.
Q: What is AI’s role in computational drug design?
A: Designing a drug for a specific site of attack in a protein – a pocket – is incredibly hard, and machine-assisted design is starting to be of enormous help in the chemical-space exploration. As an analogy, imagine you have to build a key for a lock you don’t know in detail – an experienced locksmith can possibly take days or weeks of trial and error, while if you could ask a supercomputer to create and try millions of keys and test them on the numerical model of the lock, you could speed up this process by orders of magnitude.
Q:How are supercomputers helping?
A: To compute, and then predict, if a drug will engage a pocket of a protein correctly or not, you first have to solve an incredibly hard numerical problem: the quantum mechanical interactions of all the atoms in the protein – tens of thousands – with the drug. At this scale only a large supercomputer has enough memory and CPU power to solve one of these configurations in a reasonable time and iterate it on the thousands of drugs the research team wants to try.
Q:What are the main challenges of computational drug design?
A: There are still many mathematical challenges to solve. The bare simulation of all atoms is often infeasible even for the largest supercomputer, and we need smarter methods to reach a solution more quickly. Protein-folding algorithms using meta-dynamics as well as machine learning-driven solutions or evolutions of these concepts are very exciting, as they help us save trillions of computations and scale faster to more and more targets and proteins.
Q:In a recent interview with Forbes, you mentioned the importance of customized drug design in the fight against cancer. Is this something you are currently working on, and could you tell us a little more about it?
A: Oncogenes, a term referring to the mutated proteins helping cancer to survive and spread, are fundamentally important targets to “attack” with small molecules. The more precision we get in cancer sequencing and in drug-mutationsmatching, the better we’ll be able to deliver precise therapeutics. It’s a long process, and I promise to keep you updated!
THIS WEBSITE (AND THE INFORMATION CONTAINED HEREIN) DOES NOT CONTAIN OR CONSTITUTE AN OFFER OF SECURITIES FOR SALE, OR SOLICITATION OF AN OFFER TO PURCHASE SECURITIES OR IS NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES (INCLUDING ITS TERRITORIES AND POSSESSIONS, ANY STATE OF THE UNITED STATES AND THE DISTRICT OF COLUMBIA) OR FOR THE ACCOUNT OR BENEFIT OF ANY U.S. PERSON AS THAT TERM IS DEFINED IN THE SECURITIES ACT (A "U.S. PERSON"), AUSTRALIA, CANADA, JAPAN OR SOUTH AFRICA OR ANY OTHER JURISDICTION WHERE SUCH AN OFFER OR SOLICITATION WOULD REQUIRE THE APPROVAL OF LOCAL AUTHORITIES OR OTHERWISE BE UNLAWFUL (THE "OTHER COUNTRIES"). THE SECURITIES REFERRED TO HEREIN HAVE NOT BEEN AND WILL NOT BE REGISTERED UNDER THE U.S. SECURITIES ACT OF 1933, AS AMENDED (THE "SECURITIES ACT"), OR PURSUANT TO THE CORRESPONDING REGULATIONS IN FORCE IN AUSTRALIA, CANADA, JAPAN, SOUTH AFRICA OR THE “OTHER COUNTRIES” AND MAY NOT BE OFFERED OR SOLD IN THE UNITED STATES OR TO A U.S. PERSON UNLESS THE SECURITIES ARE REGISTERED UNDER THE SECURITIES ACT, OR AN EXEMPTION FROM THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT IS AVAILABLE. NO PUBLIC OFFERING OF SUCH SECURITIES IS INTENDED TO BE MADE IN THE UNITED STATES, AUSTRALIA, CANADA, JAPAN OR IN THE “OTHER COUNTRIES.”
In any Member State of the European Economic Area ("EEA"), the information contained in this website is only directed at and may only be communicated to persons who are "qualified investors" ("Qualified Investors") within the meaning of Article 2(e) of Regulation (EU) 2017/1129 (the "Prospectus Regulation").
The information to which this website gives access is directed only at persons (i) who are persons falling within Article 49(2)(a) to (d) ("high net worth companies, unincorporated associations etc.") of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (the "Order") or (ii) who have professional experience in matters relating to investments falling within Article 19(5) of the Order or (iii) to whom it may otherwise lawfully be communicated (all such persons together being referred to as "relevant persons"). Any investment or investment activity to which this communication relates is only available to relevant persons and will be engaged in only with relevant persons, or in the EEA, with Qualified Investors. Any person who is not a relevant person, a Qualified Investor or otherwise permitted under applicable law or regulation to access the information, should not act or rely on the information contained herein.
Confirmation of Understanding and Acceptance of Disclaimer
These materials are for informational purposes only and are not directed to, nor are they intended for, access by persons located or resident in the United States, Australia, Canada, Japan or South Africa or any of the Other Countries. I certify that:
I am not resident of, or located in, the United States, Australia, Canada, Japan or South Africa or any of the Other Countries or I am not a U.S. Person; or
If I am a resident of, or located in, the EEA, I am a Qualified Investor within the meaning of Article 2(e) of the Prospectus Regulation; or
If I am a resident of, or located in, the United Kingdom, I am a Qualified Investor and a relevant person.
I have read and understood the disclaimer set out above. I understand that it may affect my rights. I agree to be bound by its terms and I am permitted under applicable law and regulations to proceed to the following parts of this website.
WARNING: the above certification constitutes a "self-certification" pursuant to Decree of the President of the Italian Republic No. 445 of 28 December 2000. False certifications are punishable by law.
You must read the following information before continuing.
The information contained in this segment of the website is not intended for, and must not be accessed or distributed or disseminated to persons resident or physically present in the United Kingdom, Canada, Australia, Japan or any other jurisdiction in which it is unlawful to do so. The information also is not intended for, and must not be accessed or distributed or disseminated to persons resident or physically present in Italy who are not “qualified investors” (investitori qualificati), as defined in Article 2, letter e) of Regulation (EU) 2017/1129 (the “Prospectus Regulation”) pursuant to Article 1, fourth paragraph, letter a) of the Prospectus Regulation as implemented in Italy by Article 35, paragraph 1, letter d) of CONSOB regulation No. 20307 of February 15, 2018.
By clicking the button below labeled “I agree”, you are certifying that (A) if you are in the European Economic Area, you are a “Qualified Investor”; (B) you are not accessing this portion of the website from the United Kingdom, Australia, Canada or Japan; (C) if you are a resident or physically present in Italy, you are a qualified investor as defined under the Prospectus Regulation as implemented in Italy by Article 35, paragraph 1, letter d) of CONSOB regulation No. 20307 of February 15, 2018; and (D) you are not located in a jurisdiction where it is unlawful to access this portion of the website.
You acknowledge that the information and statements contained in the document you are accessing on this website speak only as of the date of such document (or such other date(s) specified therein), and such information and statements may become inaccurate, stale and/or out-of-date thereafter and should not be relied upon for any investment decision.
You acknowledge that the materials on this website that you are accessing are confidential and intended only for you and you agree you will not forward, reproduce, copy, download or publish any of such materials (electronically or otherwise) to any other person if this is not in accordance with the law.
You acknowledge that the access to information and documents contained on this portion of the website may be illegal in certain jurisdictions, and only certain categories of persons may be authorized to access this portion of the website. If you are not authorized to access the information and document contained on this portion of the website or you are not sure that you are permitted to view these materials, you should leave this portion of the website.
You acknowledge that no registration or approval has been obtained and Eni Gas e Luce S.p.A. società benefit and its affiliates assume no responsibility if there is a violation of applicable law and regulation by any person.
By clicking the button below labeled “I agree”, you are confirming that you have read and understood the disclaimer above.
If you cannot so confirm, you must exit this portion of the website